For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Cellular Autoimmune Mechanisms of Narcolepsy Study

Clinical Trial Title: 
Study on the cellular autoimmune mechanisms of narcolepsy.
Clinical Trial Protocol ID: 
16062904
Clinical Trial Investigator Name: 
Igor J. Koralnik, MD
Clinical Trial Protocol Description: 

The purpose of this study is to determine whether narcolepsy patients with cataplexy exhibit an autoimmune response against the peptide orexin, which is depleted in this condition. A blood sample of 30 mL (about 2 tablespoons) will be taken to measure the participant’s cellular immune response against orexin. Subjects will also be tested for a DQB1 allele that is strongly linked to narcolepsy with cataplexy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are at least 6 years of age.

You will be excluded from the study if any of the following criteria apply to you:

  • Have narcolepsy without cataplexy.
  • Have a sleep disorder other than narcolepsy.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Neurological Disorders
Sleep
Contact Phone: 
(312) 563-7317 or (312) 563-7304
Contact Name: 
Dom Tucker or Zack Orban